A Pilot Study of Cilostazol to Improve Quality of Life.

What we are studying

This is a pilot study to determine the effect Cilostazol (Pletal) has on patient quality of life and long term patency in patients who undergo either open or endovascular surgery for peripheral arterial disease.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 35+

Eligibility Criteria

  • Treated for atherosclerotic peripheral arterial disease
  • Able to provide consent
  • Lower extremity open or endovascular procedure.

What is involved

  • Quality of life questionnaires at enrollment
  • 4-6 weeks
  • 3 months
  • 6 months and 12 months.


Drug will be provided for three months. There will not be any financial compensation

Contact Information

Study Coordinator
Donna Keith
[email protected]
Principal Investigator
Nitin Garg, M.C.

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.